SCHEMBL4867766

SCHEMBL4867766

COc1ccc(S(=O)(=O)NCC(=O)N(C)c2ccc(Cl)cc2Cc2ccccc2F)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.48
MAPT P10636 2/20 0.47
MEP1B Q16820 1/20 0.43
PKM P14618 3/20 0.42
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
TP53 P04637 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 4/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KAT6A Q92794 1/20 0.41
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3246324 0.93 MAPT (0.44) MAPK1MAPTMEP1BPKMHCRTR1
SCHEMBL3250435 0.91 MAPT (0.44) MAPK1MAPTMEP1BPKMHCRTR1
SCHEMBL3263100 0.91 MAPK1 (0.57) MAPK1MAPTPKMHCRTR1HCRTR2
SCHEMBL3257032 0.89 MAPK1 (0.48) MAPK1MAPTPKMHCRTR1HCRTR2
SCHEMBL4870949 0.86 MAPK1 (0.49) MAPK1MAPTPKMHCRTR1HCRTR2
SCHEMBL4863480 0.82 ALDH1A1 (0.53) MAPK1MAPTMEP1BTP53SMN1; SMN2
SCHEMBL4872233 0.81 MAPK1 (0.55) MAPK1MAPTPKMHCRTR1HCRTR2
SCHEMBL3246229 0.80 HCRTR2 (0.49) MAPK1PKMHCRTR1HCRTR2FLT1
SCHEMBL4869109 0.80 HCRTR2 (0.57) MAPTPKMHCRTR1HCRTR2TP53
SCHEMBL4869872 0.80 MAPK1 (0.41) MAPK1MAPTFLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MAPK1 2674/4885MAPT 3113/4885MEP1B 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.